Number of responders to polyribosylribitol phosphate (PRP) antigen Post-dose 3 (12 to 13 Months) [clinicaltrials_resource:2ff0284da6f42f0e4f2570a7cdd03979]
V419 + Rotavirus vaccine + Prevenar 13
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Number of responders to polyribosylribitol phosphate (PRP) antigen Post-dose 3 (12 to 13 Months) [clinicaltrials_resource:2ff0284da6f42f0e4f2570a7cdd03979]
V419 + Rotavirus vaccine + Prevenar 13
Bio2RDF identifier
2ff0284da6f42f0e4f2570a7cdd03979
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2ff0284da6f42f0e4f2570a7cdd03979
measure [clinicaltrials_vocabulary:measure]
Number of responders to polyribosylribitol phosphate (PRP) antigen
time frame [clinicaltrials_vocabulary:time-frame]
Post-dose 3 (12 to 13 Months)
description
V419 + Rotavirus vaccine + Prevenar 13
identifier
clinicaltrials_resource:2ff0284da6f42f0e4f2570a7cdd03979
title
Number of responders to polyri ...... Post-dose 3 (12 to 13 Months)
@en
type
label
Number of responders to polyri ...... 0284da6f42f0e4f2570a7cdd03979]
@en